UNSPSC 51384514: Naproxen

This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57Y76R9ATQ, chemically known as 2-naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (s)- but generally known as naproxen, which bears US NIH Compound Identifier 1302. European Medicines Agency schedules Naproxen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09159MIG.

UNSPSC 51384514 Naproxen is a Commodity code that in practice receives state and local solicitations for pharmaceutical procurement, though the recent opportunities show activity in naloxone (an opioid reversal agent), OTC products, and direct-to-manufacturer prescription programs rather than naproxen specifically. State and local governments use this code tier for pharmaceutical acquisition to support public health initiatives, community health programs, and multi-jurisdictional pharmacy benefit management. Issuing bodies include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple states and local jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, has emerged as a significant repeat buyer, aggregating demand across participating state and local facilities nationwide.

Recent opportunities span Florida, Texas, and Minnesota with broader multistate reach. Seminole County, Florida issued IFB 60459723LAS in June 2026, with a response deadline of July 26, 2023, for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford and a two-year initial contract term with one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, designed to inform a future formal RFP. MMCAP released RFP S1070000015802 in January 2026, with responses due March 26, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products across authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), requiring cGMP and Drug Supply Chain Security Act compliance, with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative and technical factors, and a two-year initial contract term.